Featured News

The overall prevalence of celiac disease was found to be 1.6% - a much greater percentage than the 1% that researchers have been approximating for years.

The CeDLara Study is for adults who have been diagnosed with celiac disease and are still experiencing symptoms despite following a gluten-free diet.

Latiglutenase is a dual enzyme investigational product designed to break down gluten in the stomach. Learn more about the trial and what this means for celiac disease patients.

Ukko, a startup focused on eradicating food allergies, intolerances, and sensitivities, has reached a promising stage in its effort to develop a gluten specifically designed for people with celiac disease.

9 Meters Biopharma, Inc., a clinical-stage company focused on rare and unmet needs in gastroenterology, announced their collaboration with the Celiac Disease Foundation to support clinical trial enrollment.

Anokion SA announced that they have initiated patient dosing in the multiple ascending dose (MAD) portion of its ACeD study.

The ACeD Study is looking for volunteers with celiac disease to participate in a phase 1 clinical trial testing the investigational drug KAN-101.

Rep. Betty McCollum (D-MN) and Rep. Steve Stivers (D-OH) announced the formation of the Congressional Celiac Disease Caucus at the 2021 Celiac Disease Foundation Patient Education & Advocacy Summit.

With your help, we have invested significant resources into changing that reality in Washington, DC, and we are beginning to see a return on that investment.

Thank you to Glutenostics for sponsoring our upcoming Patient Education and Advocacy Summit. Through the licensing, development, and commercialization of novel technologies, Glutenostics is bringing new tools to market that address the unmet needs of millions of Americans avoiding gluten for health concerns. Register now to be a part of this monumental event!